1. Home
  2. BOE vs CTMX Comparison

BOE vs CTMX Comparison

Compare BOE & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock Enhanced Global Dividend Trust of Beneficial Interest

BOE

Blackrock Enhanced Global Dividend Trust of Beneficial Interest

N/A

Current Price

$11.34

Market Cap

632.7M

Sector

Finance

ML Signal

N/A

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

N/A

Current Price

$5.02

Market Cap

596.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BOE
CTMX
Founded
2005
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
632.7M
596.2M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
BOE
CTMX
Price
$11.34
$5.02
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$8.86
AVG Volume (30 Days)
148.9K
2.6M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
7.30%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$138,103,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$22.58
Revenue Growth
N/A
36.45
52 Week Low
$9.16
$0.40
52 Week High
$12.18
$6.35

Technical Indicators

Market Signals
Indicator
BOE
CTMX
Relative Strength Index (RSI) 26.08 46.26
Support Level $11.12 $3.83
Resistance Level $11.39 $6.20
Average True Range (ATR) 0.13 0.33
MACD -0.08 -0.10
Stochastic Oscillator 19.99 28.11

Price Performance

Historical Comparison
BOE
CTMX

About BOE Blackrock Enhanced Global Dividend Trust of Beneficial Interest

Blackrock Enhanced Global Dividend Trust has an investment objective to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. Further, it focuses on investing in a portfolio of equity securities and utilizing an option writing to seek total return performance and enhance distributions.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: